Negative trial results of custirsen for metastatic prostate cancer
Negative trial results of custirsen for metastatic prostate cancer
Cabozantinib improves PFS in metastatic renal cell carcinoma
Advances for NSCLC in review
Ceritinib following crizotinib relapse for ALK positive NSCLC
Atezolizumab v docetaxel for NSCLC: results from the OAK trial
Significant survival gains with atezolizumab for NSCLC
Pembrolizumab new option for firstline treatment of advanced lung cancer with high PDL-1 expression
Pembrolizumab plus chemo as firstline therapy for NSCLC
Pembrolizumab 'should be first line treatment' for high PD1 expressing NSCLC patients
Firstline pembrolizumab plus chemo improves NSCLC outcomes
KRAS in the clinic and conference
Firstline pembrolizumab for metastatic urothelial cancer